Humana Inc

Humana Inc (HUM) Stock Analysis

$413.160

-18.220 (-4.41%)At close

Loading chart…
High
432.400
Open
432.400
VWAP
419.11
Volume
1.41M
Mkt Cap
43.74B
Low
411.770
Amount
589.14M
EV/EBITDA, TTM
8.96

Humana Inc. provides Humana insurance services and CenterWell health care services. The Company's segments include Insurance and CenterWell. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as its contract with CMS to administer the Limited Income Newly Eligible Transition (LI-NET) prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits. This segment also includes products consisting of employer group commercial fully-insured medical and specialty health insurance benefits marketed to individuals and employer groups. The CenterWell segment includes its pharmacy, primary care, and home solutions operations. The segment also includes its strategic partnerships with WCAS to develop and operate senior-focused, payor-agnostic, primary care centers, as well as its minority ownership interest in hospice operations.

AI analysis of Humana Inc (HUM)

Buy

Humana Inc is a good buy right now due to its recent performance and strong fundamentals. The stock is currently priced at $413.16, which is below the analyst price target range of $475 to $525, indicating potential upside. Additionally, the company has improved its Medicare Advantage ratings significantly, with 95% of its members now in plans rated four stars or higher, which could lead to an estimated $3.6 billion in additional revenue. However, the main risk is the recent decline in stock price, with a 5-day change of -4.33%.

Analyst Ratings (19)

-29.71% Downside
Buy
12 Buy
7 Hold
0 Sell
Current: 413.16
Low
231.00
Average
290.39
High
344.00

UBS

2026-10-12

Price Target

$495

Neutral

Oppenheimer

2026-10-12

Price Target

$525

Outperform

Truist

2026-10-12

Price Target

$475

Hold

Raymond James

2026-10-12

Price Target

$520

Outperform

Oppenheimer

2026-10-09

Price Target

$475

Outperform

Valuation Metrics

The current forward P/E ratio for Humana Inc (HUM) is 24.33, compared to its 5-year average forward P/E of 20.22.

Forward P/E

Fair
5Y Average P/E
20.22
Current P/E
24.33
Overvalued
26.14
Undervalued
14.31

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
10.62
Current EV/EBITDA
8.96
Overvalued
14.53
Undervalued
6.72

Forward P/S

Fair
5Y Average P/S
0.42
Current P/S
0.31
Overvalued
0.59
Undervalued
0.24

Alphio AI Price Scenarios for HUM

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%HUM

$253.64

Scenario price

B

Base

Base · 50%HUM

$209.60

Scenario price

B

Bear

Bear · 25%HUM

$179.91

Scenario price

Whales holding HUM

B

Braidwell LP

+ HoldingHUMTMO

+15.28%

3M Return

H

Hotchkis and Wiley Capital Management, LLC

+ HoldingHUM

+9.19%

3M Return

B

Barrow, Hanley, Mewhinney & Strauss, LLC

+ HoldingHUM

+5.18%

3M Return

P

PDT Partners, LLC

+ HoldingHUM

+5.07%

3M Return

V

Vulcan Value Partners, LLC

+ HoldingHUM

+4.99%

3M Return

S

South Dakota Investment Council

+ HoldingHUM

+4.10%

3M Return

Events Timeline

2026-10-13 (ET)

06:30:00

Humana Forms New Joint Venture with BlackRock

2026-10-09 (ET)

16:30:00

Trump Says U.S. Will Not Strike Iran, Oil Pulls Back

12:30:00

Humana Stock Rises 12.8% to $436.60

12:00:00

Tech Stock Rebound Boosts Major Averages

10:30:00

Humana Stock Rises 14.7% to $443.99

News

HUM FAQ — answered by Alphio AI

Humana Inc. provides Humana insurance services and CenterWell health care services. The Company's segments include Insurance and CenterWell. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as its contract with CMS to administer the Limited Income Newly Eligible Transition (LI-NET) prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits. This segment also includes products consisting of employer group commercial fully-insured medical and specialty health insurance benefits marketed to individuals and employer groups. The CenterWell segment includes its pharmacy, primary care, and home solutions operations. The segment also includes its strategic partnerships with WCAS to develop and operate senior-focused, payor-agnostic, primary care centers, as well as its minority ownership interest in hospice operations. It operates in the Healthcare sector (HOSPITAL & MEDICAL SERVICE PLANS industry).

Humana Inc is a good buy right now due to its recent performance and strong fundamentals. The stock is currently priced at $413.16, which is below the analyst price target range of $475 to $525, indicating potential upside. Additionally, the company has improved its Medicare Advantage ratings significantly, with 95% of its members now in plans rated four stars or higher, which could lead to an estimated $3.6 billion in additional revenue. However, the main risk is the recent decline in stock price, with a 5-day change of -4.33%.

19 analysts cover HUM: 12 rate it Buy, 7 Hold and 0 Sell. The average price target is 290.39.

Community

More ↗
Sign up or log in to join the discussion

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Start trading